Glioma encompasses a heterogeneous group of primary brain tumors of astroglial/neural stem cell origin. In most cases, these tumors can be isolated and maintained in neural stem cell culture conditions where they behave alike neural stem cells and express neural stem cell markers. In adults, glioblastoma multiforme (GBM) represents the most common and deadly brain tumor and can be sub-classify in 4 types based on marker expression and cell phenotype. Though to be highly distinct from adult GBM based on the unique genetic mutation profile and resistance to temozolomide treatment, pediatric glioma may be much closer to GBM when analyzed at the chromatin level. Recent progress in genetics and chromatin biology suggests that a common finality links adult and pediatric glioma. Herein, we will discuss the implication of these findings for the development of new therapies against these deadly tumors.
Glioma Classification
Glioma represents a heterogeneous set of diseases, ranging from benign to malignant tumors. Of which, glioblastoma multiforme (GBM), a grade IV astrocytoma (WHO), represents the most common and lethal brain malignancy in adults, with a median lifespan of 9 to 15 months at time of diagnosis for primary GBM. However, current treatments regimen are palliative and can only increase lifespan by 3-4 months. Treatments involve surgical resection, ionizing radiation and chemotherapy. An effective treatment is thus needed [1] [2] [3] .
Classification of glioma in the 2007 WHO data is based on histological analysis, and tumors are graded according to the level of tumors malignancy features, wich includes necrosis, vascular proliferation, anaplasia and mitotic index [4] . However, this classification system remains limited by the heterogeneous features of gliomas, where it failed to distinguish the clinicopathologic stratification of primary GBM, which develops de novo, from secondary GBM, which develops from lower grade diffuse glioma [5, 6] . Recently, the 2016 WHO classification of CNS tumors uses, for the first time, molecular features in parallel to histology characteristics to define glioma entities. In the 2016 CNS WHO classification, glioblastoma are divided into: glioblastoma with IDH-wildtype (about 90% of cases), which is associated closely with the primary GBM, and glioblastoma with IDH-mutant (about 10% of cases), which is associated most frequently with secondary GBM (Table-1). Louis et al. 2016) Many studies have attempted to group GBM into subtypes based on expression profiling [7] [8] [9] [10] [11] [12] [13] . Phillips et al. in 2006 suggested three subclasses based on the dominant gene expression patterns of 107 samples using DNA microarray [7] . Afterward, Verhaak et al. described four subtypes of GBM based on a 840 genes profile: classical, proneural (PN), mesenchymal (MES) and neural [8] . Even though there is no exact GBM subgroup definition, there is a clear demarcation between PN and MES subgroup. The MES subtype has been associated with more invasive tumor, which is also displaying more necrosis and angiogenesis. Primary GBM is predominant in the MES group, which is associated with poorer prognosis. In contrast, the PN subgroup is strongly associated with secondary GBM, which has a better prognosis [7] . Interestingly, Pillips et al. demonstrated a shift in GBM subgrouping from PN to MES signature upon tumor recurrence [7] . Pediatric brain tumors represent the most common solid tumor in children. Unlike adult brain tumors, where high-grade glioma (HGG) is prevalent, low-grade For the purpose of this review, all pediatric glioma will be referred as pHGG.
The Cell of Origin
In most cancers, the quest for the identity of the tumor-initiating cell (TIC) is the Holy Grail as it may provide new avenues to develop efficient therapies. (ii) expression of some of these markers may be lost owing to epigenetic silencing, and/or (iii) their expression may vary between glioma subtypes. In this regard, the unequivocal identification of glioma CSCs is a must as they form the entity that continually fuels the tumor mass, and they are responsible for resistance to radiation therapy and chemotherapy [74, 75] . In addition, these cells could hold for a valuable screening platform for new therapeutics. In fact, and in contrary to glioma cell lines, histological and gene expression pattern analyses have shown a strong correlation between the original patient tumor and tumors derived from CSCs [66].
Genetics
Inhibition of tumor suppressors and activation of cell proliferation through oncogenes represent the main limitation events in cancer development. Induction of angiogenesis, DNA dammage repair, invasion and drug resistance mechanisms are often responsible for the proliferation of high grade tumors that are extremely challenging to treat and more prone to recurrence.
In the adult population, TP53, RB1, NF1, CDKN2A and PTEN are all tumor suppressors found to be deleted or mutated in glioma. Inactivation of the p53 pathway was also delineated by ARF deletions and MDM2 or MDM4 amplifications [76] . Aberrations in the RB pathway was mostly caused by deletion of CDKN2A/CDKN2B followed by CDK4 locus amplification. Dysregulation of growth factor signaling through amplification and activating mutations of receptor tyrosine kinases (RTKs) also represent an important genetic event. Aberrant expression of protooncogenes such EGFR, ERBB, PDGFRA, MET and BRAF has been commonly identified ( Figure 2) In contrast, pHGG is linked to a limited number of driver mutations that account for aberrant DNA copy number and altered gene expression (Figure 2) Since H3K27me3 deposition can be reversed by de-methylase activities of the KDM6-family proteins JMJD3 and UTX, it was tested whether inhibition of KDM6 using GSK-J4 could increase H3K27me3 levels and thus impact of tumor growth. Notably, K27M-carrying pHGG, but not wild type pHGG, were found to be specifically sensitive to KDM6 inhibition, thus providing the fist hint for possible application of epigenetic drug therapy [133] . Similarly, Grasso et al. screened chemotherapeutic and epigenetic compounds for their activity on pHGG. They found that the histone deacetylase inhibitor (HDACi) panobinostat was effective at reducing cancer cell growth in part through induction of both H3K27 tri-methylation and H3 acetylation. The combination with GSK-J4 also provided "synergistic" activity against tumor growth in vitro and in xenograft mouse models [134] .
In K27M-carrying glioma, PRC2 was previously found to accumulate at H3.3 poor loci, resulting in gene repression [132] . One of the loci affected by this phenomena is the INK4A locus, the main target of PRC1 and PRC2 repressive activities [135, 136] . The INK4A locus is frequently deleted in cancers and encodes for the p16INK4a and p14ARF tumor suppressors, which act on the Rb and p53 pathways, respectively [137] . Notably, EZH2 inhibition with the small compounds GSK343 or EPZ6438 in INK4A-proficient pHGG carrying the K27M mutation resulted in significant tumor regression [135] . At the molecular level, it was discovered that H3K27M heterotypic nucleosomes where hyper-acetylated at lysine 27 (H3K27ac), resulting in recruitment of the BET bromodomain proteins BRD2 and BRD4, of RNA PolII and elevated transcription, reminiscent of the structure found at "super-enhancers". Pharmaceutical inhibition of BET bromodomain proteins with JQ1 in pHGG resulted in neural differentiation in part through transcriptional down-regulation of "super activated" loci, including GLI2, which is known to regulates the activity of the cancer-promoting sonic hedgehog (Shh) pathway [138-141]. Likewise, pHGG carrying the G34R/V mutation or SETD2 loss-of-function have reduced levels of H3K36me3, which correlated with activation of developmental genes and of MYCN [142, 143] , altogether suggesting the presence of a common "chromatin signature" for pHGG.
The Chromatin Hub
Although adult and pediatric glioma have variable developmental and cellular origins and carry distinct combinations of genetic anomalies, yet they may share a common "chromatin hub", as suggested by their mutual relationship with Polycomb group proteins ( Figure  3) . Many transcription factors (TFs), such as SOX2 and OLIG2, are found in glioma and operate as core TFs for gliomagenesis and tumor maintenance [43, 65, 144] . By analogy to the reprogramming of somatic cells into pluripotent stem cells with a core of 4 master TFs [145] , it was shown that over- [146] . Likewise, ectopic expression of SOX2, OLIG2 and ZEB1 was found sufficient to convert tumor suppressor-deficient astrocytes into gliomainitiating cells, and this independently of RTK amplification or gain-of-function mutations [147] . Interestingly, previous work showed that Bmi1 over-expression was sufficient to "reprogram" mouse astrocytes into neural stem cells [148] or mouse retinal progenitors into retinal "stem cells" by conferring self-renewal properties [149] .
Additional TFs and chromatin remodelers, such as TLX, ZFHX4 and MLL5, were found to be abundant in glioma CSCs and required for their self-renewal [150] [151] [152] . While the intricate relationship between these factors in CSC biology remains to be elucidated, one can speculate that they form a network of self-reinforcing TFs that confer CSC identity in part by repressing alternative cell fates.
Figure 3. The Chromatin Hub
Model of the glioma genetic and epigenetic complexity and evolution over time is showed. While genetic complexity within groups and between groups is very large, epigenetic complexity tends to diminish, to ultimately reach the least variable constriction point referred to as the Chromatin Hub. The Chromatin Hub is defined by the presence of nework of core transcription factors (TFs) that are essential to maintain the self-renewal properties of cancer stem cells. Targeting Chromatin Hub's components holds therapeutic promises against glioma but at a risk of inducing an irreversible epigenetic drift of the tumor. This led to the proposition that epigenetic circuits superimposed upon genetic mutations determine key features of cancer cells, and possibly the CSC phenotype [146] . Notably, glioma cells treated with RTK inhibitors can rapidly adapt by adopting a "persister-like" state involving EZH2 downregulation and KDM6 upregulation, re-distribution of repressive chromatin marks and activation of developmental genes [153] . This situation is reminiscent of the chromatin phenotype of pHGG carrying the K27M or G34R/V mutations. Interestingly, MLL5, the most divergent member of the mixed lineage leukemia (MLL) gene family, is highly expressed in adult GBM. MLL5 represses H3F3B transcription (encoding for H3.3) and this preferentially in CD133+ cells. Inactivation of MLL5 increased H3.3 levels, leading to loss of specific (yet uncharacterized) heterochromatin domains and deficiency in CSC self-renewal through differentiation [152] . Thus, MLL5 antagonizes H3.3 accumulation (and by inference H3.3K27me3 accumulation) to promote CSC self-renewal, which is also reminiscent of pHGG with H3.3K27M mutation.
The implication of these findings is that despite their notable divergences in mutational spectrum, developmental timepoint and cellular origin, adult and pediatric glioma may both depend on a common "chromatin hub" that is critical to sustain CSC self-renewal (Figure 3) . Targeting chromatin hub components may be the key to cure disease.
Therapeutic Perspectives
Despite numerous efforts, the treatment of glioma remains highly challenging and has poorly evolved in the past decades. Epigenetic therapies for pHGG using KDM6, HDAC, BET or EZH2 inhibitors show promises in mouse models, but still have to show efficacy in patients (reviewed in [154, 155] ). Combined epigenetic therapy using panobinostat and GSK-J4 apparently displays synergistic effect at suppressing tumor growth [134] . GSK-J4 was also reported to inhibit the colony formation capacity of freshly isolated adult GBM cells in vitro [152] . However, none of these treatments were shown to cure the disease in mouse models, raising concern about their possible translational application to humans.
BMI1 is implicated in DNA damage response and maintenance of genomic stability, which may open new avenues for multimodal therapies [121, [156] [157] [158] . Recently, this dual strategy proved to be effective in a mouse model of head and neck squamous cell carcinoma where BMI1 inhibition sensitized otherwise resistant CSCs to cisplatin treatment and eliminate lymph node metastasis and tumor bulk [159] .
Notably, a BMI1 inhibitor has been tested in human colorectal tumors containing CSCs and was shown to inhibit cell growth and improve lifespan in grafted animals [160] . Notably, panobinostat may sensitize cells to DNA damage since it was shown to display significant therapeutic activity only when combined with radiation treatments in clinical assays [154] . Thus, combinatorial therapies involving epigenetic drugs and classical DNA-damaging agents may synergize to eliminate CSC and cure the disease. Also, since epigenetic therapy can promote epigenetic drift (Figure 3) [131], combination with another epigenetic agent blocking the alternate differentiation program together with radio-or chemotherapy may prove extremely effective. Extensive characterization of the cancer cell response to these epigenetic compounds is thus a pre-requisite to an intelligent design of drug combinations and treatments. 
